Stereotactic body radiotherapy for early-stage non-small cell lung cancer: a multicentre study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

Ots, P.M. Samper; Ocaña, C. Vallejo; Martín, M.; Alvarez, F.J. Celada; Albiol, Dolores Farga; Blanco, P. Almendros; Machancoses, Ana Hernández; Rico, M.; Andueza, S. Flamarique; Ruperto, F. Romero; Bueno, Coralia; Escobar, E. Amaya; Gómez, Luis Leonardo Guerrero; Couñago, Felipe; Alcantara, M.; Villar, M. J. Ruiz Pérez de; Antón, J.L. Monroy; Bueno, P Saez; Tirado, J. Luna; Puertas, M.D.M.; Bobo, A.; Martinez, Isaac; Costoso, N. Gascon; Albiach, C. Ferrer

doi:10.1007/s12094-021-02697-4

Cited by 4 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of LC and survival, smaller tumor size, good performance status, non-squamous cell carcinoma histology, lesion SUVmax ≤ 5, the presence of oligometastases, response, and BED 10 values have been reported as favorable factors in many studies [ 4 , 11 , 12 , 26 ]. In a Spanish study, for early-stage lung cancer, CR was 54% with CT or PET/CT at 3 months following SBRT, and only CR was associated with local and distant control [ 28 ]. Increased glucose metabolism on PET/CT was also reported to be significant for CR (59% vs. 31%).…”

Section: Discussionmentioning

confidence: 99%

Results of Stereotactic Body Radiotherapy With CyberKnife-M6 for Primary and Metastatic Lung Cancer

Sarihan,

Tunc,

Irem

et al. 2024

World J Oncol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Results of Stereotactic Body Radiotherapy With CyberKnife-M6 for Primary and Metastatic Lung Cancer

Sarihan,

Tunc,

Irem

et al. 2024

World J Oncol

View full text Add to dashboard Cite

“…Other groups have reported that the biologically effective dose (BED) is also related to the prognosis of patients treated with SBRT for early-stage NSCLC [ 18 ]. Clinical T stage, tumor size, and total radiation dose also had a statistically significant impact on survival outcomes of patients with early-stage NSCLC treated with SBRT [ 19 , 20 ]. Nowadays, many quantitative features can be extracted from radiographic images using radiomics.…”

Section: Introductionmentioning

confidence: 99%

Establishment of a Prediction Model for Overall Survival after Stereotactic Body Radiation Therapy for Primary Non-Small Cell Lung Cancer Using Radiomics Analysis

Sawayanagi

Yamashita

Nozawa

et al. 2022

Cancers

View full text Add to dashboard Cite

Stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) leads to recurrence in approximately 18% of patients. We aimed to extract the radiomic features, with which we predicted clinical outcomes and to establish predictive models. Patients with primary non-metastatic NSCLC who were treated with SBRT between 2002 and 2022 were retrospectively reviewed. The 358 primary tumors were randomly divided into a training cohort of 250 tumors and a validation cohort of 108 tumors. Clinical features and 744 radiomic features derived from primary tumor delineation on pre-treatment computed tomography were examined as prognostic factors of survival outcomes by univariate and multivariate analyses in the training cohort. Predictive models of survival outcomes were established from the results of the multivariate analysis in the training cohort. The selected radiomic features and prediction models were tested in a validation cohort. We found that one radiomic feature showed a significant difference in overall survival (OS) in the validation cohort (p = 0.044) and one predicting model could estimate OS time (mean: 37.8 months) similar to the real OS time (33.7 months). In this study, we identified one radiomic factor and one prediction model that can be widely used.

show abstract

Stratification of tumour cell radiation response and metabolic signatures visualization with Raman spectroscopy and explainable convolutional neural network

Fuentes,

Milligan,

Wiebe

et al. 2024

Analyst

View full text Add to dashboard Cite

show abstract

Stereotactic body radiotherapy for early-stage non-small cell lung cancer: a multicentre study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

Cited by 4 publications

References 29 publications

Results of Stereotactic Body Radiotherapy With CyberKnife-M6 for Primary and Metastatic Lung Cancer

Results of Stereotactic Body Radiotherapy With CyberKnife-M6 for Primary and Metastatic Lung Cancer

Establishment of a Prediction Model for Overall Survival after Stereotactic Body Radiation Therapy for Primary Non-Small Cell Lung Cancer Using Radiomics Analysis

Stratification of tumour cell radiation response and metabolic signatures visualization with Raman spectroscopy and explainable convolutional neural network

Contact Info

Product

Resources

About